公开(公告)号：EP1038529A2

公开(公告)日：2000-09-27

申请号：EP00105361.0

申请日：2000-03-17

申请人： NIPPON ZOKI PHARMACEUTICAL CO., LTD.

发明人： Konishi, Jin-emon, Nippon Zoki Pharmac. Co., Ltd. ,  Ansari, Aftab A. ,  Gershwin, Eric M., c/o University of California

IPC分类号： A61K35/36

CPC分类号： A61K35/36

摘要： The present invention concerns the use of an extract from inflammatory tissue inoculated with vaccinia virus as active component in an agent for increasing chemokine production which is useful for the treatment of AIDS. The extracts from inflammatory tissue inoculated with vaccinia virus have increasing effects in the production of chemokines such as MIP-1α, MIP-1β and RANTES which are HIV-suppressive factors released from CD8 + T cells. The extracts also have suppressive effects on SIV infection and on SIV replication. Therefore, such an extract is useful in an anti-HIV drug with new mechanisms of action which are different from those of known therapeutic agents for AIDS such as reverse transcriptase inhibitors and protease inhibitors, and an agent comprising this extract is very useful as a new drug for the treatment of AIDS with high safety.

摘要翻译： 本发明涉及将用痘苗病毒接种的炎性组织的提取物作为活性成分用于增加趋化因子产生用于治疗AIDS的趋化因子的用途。 接种痘苗病毒的炎症组织的提取物在生产趋化因子如MIP-1α，MIP-1β和RANTES方面具有增加的作用，它们是从CD8 + T细胞释放的HIV抑制因子。 提取物也对SIV感染和SIV复制具有抑制作用。 因此，这种提取物可用于具有与已知的AIDS治疗剂如逆转录酶抑制剂和蛋白酶抑制剂不同的新作用机制的抗HIV药物，并且包含该提取物的药剂作为新的药物是非常有用的 药物治疗艾滋病高度安全。

公开(公告)号：EP0821592A4

公开(公告)日：2000-03-01

申请号：EP96912950

申请日：1996-04-19

申请人： UNIV PENNSYLVANIA ,  UNIV NEW YORK

发明人： LAVKER ROBERT M ,  SUN TUNG-TIEN ,  YU DA-WEN

IPC分类号： A61K38/22 ,  A61K45/00 ,  A61P43/00 ,  C12N5/071 ,  A61K38/48 ,  A61K7/06 ,  A61K35/36 ,  A61K38/19 ,  A61K38/57 ,  C12N5/00

CPC分类号： C12N5/0627 ,  C12N2501/998

摘要： A method of modulating hair growth by contacting selected cells with a selected growth-modulating molecule is provided. A method for hair reconstitution or transplantation by expanding selected cells in vitro and combining them with other cells that regulate hair growth are also provided. Compositions containing a growth-modulating molecule which is synthesized by follicular cells and which undergoes hair-cycle-dependent concentration changes in hair follicles are also provided.

摘要翻译： 提供了通过使所选择的细胞与选择的生长调节分子接触来调节毛发生长的方法。 还提供了通过在体外扩展选定细胞并将其与调节毛发生长的其它细胞组合的毛发重建或移植的方法。 还提供了含有通过滤泡细胞合成并且在毛囊中经历毛发周期依赖性浓度变化的生长调节分子的组合物。

公开(公告)号：EP0957161A1

公开(公告)日：1999-11-17

申请号：EP97949237.8

申请日：1997-12-25

申请人： Kirin Brewery Company, Ltd.

发明人： KOEZUKA, Y. Kirin Brewery Company, Ltd. ,  YAMAGUCHI, Y. Kirin Brewery Company, Ltd ,  MOTOKI, K. Kirin Brewery Company, Ltd.

IPC分类号： C12N5/22 ,  C07H15/04 ,  A61K35/14 ,  A61K35/28 ,  A61K35/36

CPC分类号： C07H15/04 ,  A61K2039/5154 ,  C12N5/0639 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/90

摘要： A method for activating human antigen presenting cells characterized by culturing in vitro antigen presenting cells with a human origin together with at least one of glycoside compounds represented by general formula (A) or salts thereof preferably exemplified by (2S, 3S, 4R)-1-(α-D-galactopyranosyloxy)-2-hexacosanoylamino-3,4-octadecanediol; the human antigen presenting cells thus activated; methods for treating cancer or infectious diseases such as AIDS by using activated human antigen presenting cells; and the use of activated human antigen presenting cells in the production of drugs for treating these diseases. Thus, sufficient therapeutic effects can be achieved on cancer and infectious diseases such as AIDS without effecting any pulse therapy with the use of tumor antigens.

摘要翻译： 一种用于激活通过在体外培养的抗原与由通式（A）代表的糖苷化合物中的至少一种呈递细胞与人源一起表征的人抗原呈递细胞或其盐优选通过（2S，3S，4R）例举方法-1 - （α-D-半乳糖吡喃糖基）-2-二十六烷基-3,4-十八烷二醇; 人抗原呈递细胞如此活化; 方法用于治疗癌症或感染性疾病：通过使用活化的人的抗原呈递细胞，如艾滋病; 并在生产药物的用途激活的人体的抗原呈递细胞用于治疗疾病的论文。 因此，足够的治疗效果可在癌症和感染性疾病来实现：例如AIDS，而不会影响任何脉冲疗法与使用肿瘤抗原。

公开(公告)号：EP0953352A1

公开(公告)日：1999-11-03

申请号：EP99107436.0

申请日：1999-04-27

申请人： NIPPON ZOKI PHARMACEUTICAL CO., LTD.

发明人： Konishi, Jin-emon ,  Fukuhara, Koki

IPC分类号： A61K35/36

CPC分类号： A61K35/76 ,  A61K35/36 ,  A61K2300/00

摘要： An object of the present invention is to offer a therapeutic agent for ischemic diseases having little side effects and being capable of administering safely.
The effective component of the therapeutic agent for ischemic diseases of the present invention is an extract from inflammatory tissue inoculated with vaccinia virus.
An extract from inflammatory tissue inoculated with vaccinia virus. protects a cell against damage by suppressing abnormal depolarization of hyppocampal pyramidal neurons during hypoxia and so can delay the time falling into cell death. The characteristic action is not observed for normal pyramidal neurons, but is expressed only in the stage of pathema during hypoxia. Therefore, the substance of the present invention is useful as a drug to treat and prevent ischemic diseases such as cerebral infarction and the like and symptoms accompanying with neuropathy caused by ischemia.

摘要翻译： 本发明的目的在于提供一种副作用少，能够安全地施用的缺血性疾病的治疗剂。 本发明的缺血性疾病治疗剂的有效成分是接种痘苗病毒的炎性组织的提取物。 来自接种痘苗病毒的炎症组织的提取物。 通过在缺氧期间抑制超氧化物锥体神经元的异常去极化来保护细胞免受损伤，因此可以延缓细胞死亡的时间。 正常金字塔神经元没有观察到特征性作用，但仅在缺氧期间的病变阶段表达。 因此，本发明的物质可用作治疗和预防缺血性疾病如脑梗死等的药物和伴随神经缺血引起的神经病变的症状。

公开(公告)号：EP0700297A4

公开(公告)日：1997-04-09

申请号：EP94919227

申请日：1994-05-24

申请人： UNIV JOHNS HOPKINS

发明人： BESCHORNER WILLIAM E

IPC分类号： C12N5/06 ,  A01K67/027 ,  A61K35/12 ,  A61K35/14 ,  A61K35/28 ,  A61K35/36 ,  A61K35/39 ,  A61K35/407 ,  A61K39/00 ,  A61P37/06 ,  A61K35/00 ,  C12N5/00

CPC分类号： A61K35/28 ,  A01K67/0271 ,  A61K35/15 ,  A61K35/26 ,  A61K39/001 ,  A61K2039/5154

摘要： PCT No. PCT/US94/05844 Sec. 371 Date Jun. 6, 1995 Sec. 102(e) Date Jun. 6, 1995 PCT Filed May 24, 1994 PCT Pub. No. WO94/27622 PCT Pub. Date Dec. 8, 1993This invention provides a method for developing immune tolerance in xenogeneic organ graft recipients, in which lympho-hematopoietic cells from an intended organ graft recipient are differentiated within a xenogeneic surrogate, such as a fetal animal. After birth of the surrogate, the matured lympho-hematopoietic cells containing antigen specific regulatory cells, including suppressor cells, veto cells, select B cells, anti-idiotype antibodies, and other related factors responsible for antigen specific tolerance in a surrogate animal are reintroduced into the intended organ graft recipient, in conjunction with an organ transplant or a tissue transplant from the xenograft surrogate. The invention also provides an organ graft repopulated with cells from the intended organ graft recipient produced in a surrogate animal.

摘要翻译： PCT号 PCT / US94 / 05844秒。 371日期1995年6月6日二段。 102（e）中的日期1995年6月6日提交的PCT 1994年5月24日的PCT公布。 号 WO94 / 27622的PCT公布。 日期十二月 8，1993This发明提供一种用于显影在异种器官移植受者的免疫耐受性，其中，从在预期器官移植受体淋巴造血细胞是异种替代内分化，检查作为胎儿动物的方法。 代孕出生后，含有抗原特异性调节细胞，包括抑制细胞，否决细胞，选择B细胞，抗独特型抗体，并负责代孕动物抗原特异性耐受其他相关因素的成熟淋巴造血细胞重新进入 意器官移植受体中，结合器官移植或从异种移植物替代物的组织移植。 因此本发明提供与从旨在以替代动物产生的器官移植受体细胞重新填充的器官移植物。

公开(公告)号：EP0610345A4

公开(公告)日：1997-01-15

申请号：EP92922624

申请日：1992-10-14

申请人： CELL GENESYS INC

发明人： SHERWIN STEPHEN A ,  DUBRIDGE ROBERT B

IPC分类号： A61K38/00 ,  A61K35/12 ,  A61K35/36 ,  A61K38/13 ,  A61K39/00 ,  A61P37/06 ,  A61K37/00

CPC分类号： A61K39/001 ,  A61K31/436 ,  A61K35/36 ,  A61K38/13 ,  C12N2510/00 ,  A61K2300/00

摘要： Novel regimens are provided for administering foreign genetically modified allogeneic cells to a host by combining the administration of the cells with a reduced regimen of an immunosuppressive agent. Particularly, cells having a reduced level of Class I MHC antigens may be employed in a variety of cellular therapy situations, where foreign cells are engrafted to treat diseased states.

公开(公告)号：EP0675728A4

公开(公告)日：1996-07-17

申请号：EP93920392

申请日：1993-08-27

申请人： OREGON STATE

发明人： BURGESON ROBERT E ,  LUNSTRUM GREGORY P ,  ROUSSELLE PATRICIA ,  MARINKOVICH M PETER

IPC分类号： A61K38/00 ,  A61K35/36 ,  A61K38/39 ,  A61L27/22 ,  A61L27/60 ,  A61P43/00 ,  C07K14/47 ,  C07K14/78 ,  C07K16/18 ,  C12N5/00 ,  C12N5/071 ,  C12N5/08 ,  C07K15/06 ,  C07K15/14

CPC分类号： C12N5/0629 ,  A61K35/36 ,  A61K38/39 ,  A61L27/227 ,  A61L27/60 ,  C07K14/47 ,  C07K14/78 ,  C07K16/18 ,  C12N5/0068 ,  C12N2501/58 ,  C12N2533/52 ,  A61F2/10

摘要： The isolated proteins kalinin and k-laminin are disclosed to provide adhesion between epidermal keratinocytes and the underlying dermis. Purified kalinin has a molecular weight of approximately 410-495 kDa and exists in a cell-associated form (about 495 kDa) and two medium-associated forms (about 460 and 410 kDa, respectively). The k-laminin adhesion molecule is an isolated heterotrimeric laminin variant that has a molecular weight of about 650 kDa and separates on western blots into first and second fragments that are similar to the B1 and B2 fragments of laminin and a third fragment of 190 kDa that is immunoreactive with a monoclonal antibody BM165, an antibody that is specific to kalinin. Methods of using kalinin or k-laminin for improving adhesion of transplanted keratinocytes to an underlying substrate are disclosed.

公开(公告)号：EP0522078A4

公开(公告)日：1993-05-26

申请号：EP91908003

申请日：1991-03-22

申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH

发明人： HOUGHTON, ALAN, N. ,  VIJAYASARADHI, SETALURI

IPC分类号： C12N15/11 ,  A61K31/65 ,  A61K35/36 ,  A61K38/00 ,  A61K39/00 ,  A61K48/00 ,  A61P35/00 ,  C07K14/47 ,  C12N9/02 ,  C12N15/09 ,  C12N15/12 ,  C12N15/53 ,  C12N15/63

CPC分类号： C12Y110/03001 ,  A61K38/00 ,  A61K39/00 ,  C07K14/47 ,  C12N9/0059 ,  C12N9/0071 ,  C12Y114/16002 ,  C12Y114/18001

公开(公告)号：EP0430996A4

公开(公告)日：1991-11-13

申请号：EP89909325

申请日：1989-08-04

申请人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE ,  COMPTON, CAROLYN C.

发明人： COMPTON, CAROLYN, C. ,  GREEN, HOWARD

IPC分类号： A61F2/10 ,  A61K35/12 ,  A61K35/36 ,  A61L27/60 ,  A61P17/00 ,  C12N5/071 ,  A01N63/00 ,  C12N5/00

CPC分类号： C12N5/0629 ,  A61K35/12 ,  A61K35/36 ,  A61L27/60

摘要： Tissue produced by culturing isolated epithelial cells (preferably squamous cells) will retain the ability to express the phenotypic characteristics of the isolated cells when the tissue is transplanted into a new region of body surface. Thus defects in the epithelium (e.g., burns, ulcers and congenital abnormalities) can be treated by obtaining a sample of living epidermal cells from a region of the patient's epithelium (e.g., sole of the foot, palm of the hand or scalp) having a site-specific phenotypic characteristic (e.g., a thick stratum corneum or a stratum lucidum positioned between the stratum granulosum and the stratum corneum) which is desired for the graft at the defective region. These epidermal cells are cultured, according to methods well-known to those skilled in the art, to produce transplantable living cells, e.g. an aggregation or sheet of living tissue. This tissue is then transplanted to the site of the defect where it expresses the phenotypic characteristic in a region of the patient's epithelium that may or may not ordinarily manifest this characteristic.

公开(公告)号：EP0363400A4

公开(公告)日：1990-03-16

申请号：EP88904813

申请日：1988-04-28

申请人： UNIV CALIFORNIA

发明人： BOYCE STEVEN T

IPC分类号： A61L15/16 ,  A61F2/00 ,  A61F2/10 ,  A61K35/12 ,  A61K35/36 ,  A61K38/17 ,  A61L27/00 ,  A61L27/24 ,  A61L27/38 ,  A61L27/60 ,  C12M3/00

CPC分类号： A61F2/105 ,  A61F2/10 ,  A61F2310/00365 ,  A61L27/24 ,  A61L27/36 ,  A61L27/38 ,  A61L27/60

摘要： A method and apparatus for forming a permanent, composite skin replacement consisting of an epidermal component and a porous, resorbable, biosynthetic laminated dermal membrane component for use in wound repair. The dermal membrane is formed in the apparatus, which permits regulation of variables affecting membrane structure. The dermal membrane may be modified to incorporate biologically active molecules to enhance wound repair and to reduce infection when the skin replacement is applied to a wound.